Imagine the brain's memory system as a recording device that gets stuck on 'high volume' after a trauma. This project created a specialized chemical key that turns that volume down without making the person feel drowsy or disconnected. By using it shortly after a traumatic event, it helps the brain store memories normally and prevents long-term mental health struggles.
Current PTSD treatments often fail to intervene early enough or cause severe side effects like dissociation and somnolence. There is a critical gap in therapies that can normalize stress and memory in the first year following a trauma.
A proprietary chemical entity (FENM/RST-01) and a subtype modulation platform for NMDAr receptors. The project also established a stable, scalable clinical-grade product.
If you are a drug development firm dealing with the lack of early-intervention PTSD treatments — this project developed FENM (RST-01) that targets specific brain receptors to reduce fear and anxiety. It outperforms existing molecules like Ketamine by avoiding dissociation and somnolence.
If you are a specialized clinic dealing with patients in the 1st year of PTSD — this project developed a therapy that can restore normal memorization processes. This allows for a shift in how patients are treated immediately following trauma.
If you are a CNS platform developer dealing with the side effects of NMDAR antagonists — this project developed a subtype modulation platform. This can be expanded to treat other neurological disorders beyond PTSD, such as Alzheimer Disease.
Based on available project data, specific pricing is not mentioned, but the company has improved industrial scalability to achieve COGS reduction.
ReST Therapeutics has partnered with a CDMO to improve industrial scalability and has confirmed the clinical product has superior stability at 24 months.
The company possesses a proprietary chemical entity (NCE) and is currently applying for new patents and IP expansion based on new therapeutic indications.
The company intends to submit an Investigational New Drug (IND) application with the FDA in Q4 2025.
With EIC support, the goal is to bring FENM to clinical Proof of Concept (PhIIb) by 2027.
The project is led by a single French SME, ReST Therapeutics, representing a 100% industry ratio. This lean structure indicates a high level of internal control over the IP and a direct path to commercialization, supported by a strategic academic partnership with the CNRS for expanded research.
Contact ReST Therapeutics (France) regarding their NMDAr subtype modulation platform.
Contact us to explore licensing opportunities for the FENM (RST-01) lead program.
